Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 176

Similar articles for PubMed (Select 19142173)

1.

Surgical results after preoperative chemoradiation therapy for patients with pancreatic cancer.

Satoi S, Yanagimoto H, Toyokawa H, Takahashi K, Matsui Y, Kitade H, Mergental H, Tanigawa N, Takai S, Kwon AH.

Pancreas. 2009 Apr;38(3):282-8. doi: 10.1097/MPA.0b013e31819438c3.

PMID:
19142173
2.

Two Cases of Pathological Complete Response to Neoadjuvant Chemoradiation Therapy in Pancreatic Cancer.

Fujii-Nishimura Y, Nishiyama R, Kitago M, Masugi Y, Ueno A, Aiura K, Kawachi S, Kawaida M, Abe Y, Shinoda M, Itano O, Tanimoto A, Sakamoto M, Kitagawa Y.

Keio J Med. 2015;64(2):26-31. doi: 10.2302/kjm.2014-0014-CR.

3.

Dose escalation with a vessel boost in pancreatic adenocarcinoma treated with neoadjuvant chemoradiation.

Wang LS, Shaikh T, Handorf EA, Hoffman JP, Cohen SJ, Meyer JE.

Pract Radiat Oncol. 2015 Jun 10. pii: S1879-8500(15)00152-6. doi: 10.1016/j.prro.2015.04.004. [Epub ahead of print]

PMID:
26077273
4.

Optimal indication of neoadjuvant chemoradiotherapy for pancreatic cancer.

Sho M, Akahori T, Tanaka T, Kinoshita S, Nagai M, Nishiwada S, Tamamoto T, Nishiofuku H, Ohbayashi C, Hasegawa M, Kichikawa K, Nakajima Y.

Langenbecks Arch Surg. 2015 May;400(4):477-85. doi: 10.1007/s00423-015-1304-0. Epub 2015 May 1.

PMID:
25929828
5.

[Pancreatic cancer- a curable disease].

Limani P, Samaras P, Lesurtel M, Graf R, DeOliveira ML, Petrowsky H, Clavien PA.

Praxis (Bern 1994). 2015 Apr 22;104(9):453-60. doi: 10.1024/1661-8157/a001990. Review. German.

PMID:
25900693
6.

[Preoperative chemoradiation for pancreatic cancer].

Nakamura S.

Nihon Rinsho. 2015 Mar;73 Suppl 3:159-62. Japanese. No abstract available.

PMID:
25857006
7.

[Therapy in pancreatic cancer - and still it moves along!].

Ettrich TJ, Perkhofer L, Seufferlein T.

Dtsch Med Wochenschr. 2015 Apr;140(7):508-11. doi: 10.1055/s-0041-101154. Epub 2015 Mar 31. German.

PMID:
25826035
8.

In reply.

Seufferlein T.

Dtsch Arztebl Int. 2015 Jan 23;112(4):60. doi: 10.3238/arztebl.2015.0060b. No abstract available.

9.

Ultrasound-based therapies not mentioned.

Marinova M, Rauch M, Strunk H.

Dtsch Arztebl Int. 2015 Jan 23;112(4):60. doi: 10.3238/arztebl.2015.0060a. No abstract available.

10.

Neoadjuvant chemoradiotherapy followed by D2 gastrectomy in locally advanced gastric cancer.

Kim MS, Lim JS, Hyung WJ, Lee YC, Rha SY, Keum KC, Koom WS.

World J Gastroenterol. 2015 Mar 7;21(9):2711-8. doi: 10.3748/wjg.v21.i9.2711.

11.

[After neoadjuvant therapy of pancreatic cancer the classical radiological criteria for resectability are no longer applicable].

Strobel O, B├╝chler MW.

Chirurg. 2015 Feb;86(2):183. doi: 10.1007/s00104-015-2987-z. German. No abstract available.

PMID:
25673227
12.

Feasibility of pre-operative chemoradiotherapy with gemcitabine to treat pancreatic cancer in patients with impaired renal function.

Tomimaru Y, Eguchi H, Satoh T, Tomokuni A, Asaoka T, Wada H, Marubashi S, Ogawa K, Takehara T, Mori M, Doki Y, Nagano H.

Jpn J Clin Oncol. 2015 Apr;45(4):343-8. doi: 10.1093/jjco/hyu224. Epub 2015 Jan 14.

PMID:
25589454
13.

Pancreatic cancer metastasis: are we being pre-EMTed?

Das S, Batra SK.

Curr Pharm Des. 2015;21(10):1249-55.

PMID:
25506899
14.

Preoperative gemcitabine-based chemoradiation therapy for pancreatic ductal adenocarcinoma of the body and tail: impact of splenic vessels involvement on operative outcome and pattern of recurrence.

Takahashi H, Akita H, Gotoh K, Kobayashi S, Marubashi S, Miyoshi N, Sugimura K, Motoori M, Kishi K, Noura S, Fujiwara Y, Ohue M, Ohigashi H, Yano M, Sakon M, Ishikawa O.

Surgery. 2015 Mar;157(3):484-95. doi: 10.1016/j.surg.2014.09.022. Epub 2014 Oct 16.

PMID:
25444512
15.

Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial.

Golcher H, Brunner TB, Witzigmann H, Marti L, Bechstein WO, Bruns C, Jungnickel H, Schreiber S, Grabenbauer GG, Meyer T, Merkel S, Fietkau R, Hohenberger W.

Strahlenther Onkol. 2015 Jan;191(1):7-16. doi: 10.1007/s00066-014-0737-7. Epub 2014 Sep 25.

16.

Immunohistochemical analysis of cancer stem cell markers in pancreatic adenocarcinoma patients after neoadjuvant chemoradiotherapy.

Mizukami T, Kamachi H, Mitsuhashi T, Tsuruga Y, Hatanaka Y, Kamiyama T, Matsuno Y, Taketomi A.

BMC Cancer. 2014 Sep 21;14:687. doi: 10.1186/1471-2407-14-687.

17.

Preoperative chemoradiation therapy for esophageal cancer is a risk factor for the elevation of high mobility group box-1, leading to an increase in postoperative severe pulmonary complications.

Takahata R, Ono S, Tsujimoto H, Hiraki S, Aosasa S, Yamamoto J, Hase K.

Dis Esophagus. 2014 Aug 19. doi: 10.1111/dote.12261. [Epub ahead of print]

PMID:
25139532
18.

S-1 vs. gemcitabine as an adjuvant therapy after surgical resection for ductal adenocarcinoma of the pancreas.

Okabayashi T, Shima Y, Iwata J, Morita S, Sumiyoshi T, Kozuki A, Tokumaru T, Iiyama T, Kosaki T, Kobayashi M, Hanazaki K.

World J Surg. 2014 Nov;38(11):2986-93. doi: 10.1007/s00268-014-2703-z.

PMID:
25104544
19.

Role of neoadjuvant concurrent chemoradiation in locally advanced unresectable pancreatic cancer: a feasibility study at tertiary care centre.

Kapoor R, Khosla D, Gupta R, Bahl A, Shukla AK, Sharma SC.

Indian J Cancer. 2014 Apr-Jun;51(2):176-9. doi: 10.4103/0019-509X.138295.

20.

Mucinous adenocarcinoma of the rectum: a poor candidate for neo-adjuvant chemoradiation?

Simha V, Kapoor R, Gupta R, Bahl A, Nada R.

J Gastrointest Oncol. 2014 Aug;5(4):276-9. doi: 10.3978/j.issn.2078-6891.2014.020.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk